Home > Neurology > EAN 2020 > Headache and Pain > Eptinezumab in chronic migraine and medication-overuse headache

Eptinezumab in chronic migraine and medication-overuse headache

Presented By
Prof. Hans-Christoph Diener, Medical Faculty of the University Duisburg-Essen, Germany
Conference
EAN 2020
Trial
Phase 3, PROMISE-2
In the pivotal PROMISE-2 study, eptinezumab was efficacious in patients with chronic migraine and medication-overuse headache (MOH). After 12 weeks, the eptinezumab group had a greater reduction in migraine days than the placebo group. Efficacy was noted from day 1 and sustained through 24 weeks [1]. In PROMISE-2, 1,072 chronic migraine patients participated, 431 of whom had a dual diagnosis of chronic migraine and MOH. Participants were randomised to eptinezumab 100 mg, 300 mg, or placebo for 2 intravenous doses administered every 12 weeks. Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody. MOH patients were equally distributed in these 3 groups. During the 28-day baseline period, MOH patients experienced a mean 16.7 migraine days. Efficacy of eptinezumab versus...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on